Shares of Baxalta Inc BXLT were trading higher by nearly 1 percent Wednesday after the company announced it has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for approval of its ADYNOVI.
Baxalta completed a study in patients aged 12 to 16 and its EMA filing is based on data from three Phase 3 clinical trials. ADYNOVI is already licensed in the U.S. as ADYNOVATE and under regulatory review in Japan, Canada and Switzerland.
''We are dedicated to bringing ADYNOVI to hemophilia A patients all over the world,'' said Brian Goff, executive vice president and president, Hematology, Baxalta. ''As we build on our market-leading portfolio of direct factor replacement treatments, we continually bring new options to hemophilia patients, empowering them to manage their hemophilia, with their caregivers, in the way that works best for them.''
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.